前列腺癌高场强MR-linac每日自适应放疗初步经验
该研究报告了本中心首批5例前列腺癌患者使用高场强MR-linac实施MR引导自适应放疗(MRgART)的估计分次剂量,并与C臂直线加速器每日图像引导放疗(IGRT)进行比较。MRgART和C臂直线加速器估计分别达到95%和93%的强制靶区覆盖目标及危及器官剂量约束;两种技术均估计达到98%的强制危及器官剂量约束,靶区临床目标分别达到86%和80%。结论认为前列腺癌MRgART可在高场强MR-linac上实施,参考影像解剖有利且治疗过程中解剖稳定的患者适合C臂直线加速器放疗,而参考影像上危及器官紧贴靶区的患者MRgART有潜在靶区剂量覆盖改善。
要点
- MRgART估计达到95%的强制靶区覆盖目标及危及器官剂量约束,C臂直线加速器为93%。
- 两种技术均估计达到98%的强制危及器官剂量约束。
- 靶区临床目标MRgART估计达到86%,C臂直线加速器为80%。
核心结论
- 前列腺癌MRgART可在高场强MR-linac上实施,对参考影像上危及器官紧贴靶区的患者,MRgART相比C臂直线加速器有潜在靶区剂量覆盖改善。
研究设计与样本
- 报告本中心首批5例前列腺癌患者使用高场强MR-linac实施MRgART,并将估计的分次剂量与C臂直线加速器每日IGRT方案比较。
主要发现
- MRgART和C臂直线加速器估计分别达到95%和93%的强制靶区覆盖目标及危及器官剂量约束。
- 两种技术均估计达到98%的强制危及器官剂量约束。
- 靶区临床目标由MRgART和C臂直线加速器估计分别达到86%和80%。
关键数值与推荐
- MRgART和C臂直线加速器估计分别达到95%和93%的强制靶区覆盖目标及危及器官剂量约束。
- 两种技术均估计达到98%的强制危及器官剂量约束。
- 靶区临床目标由MRgART和C臂直线加速器估计分别达到86%和80%。
临床怎么用
- 对参考影像解剖有利且治疗过程中解剖稳定的前列腺癌患者,C臂直线加速器放疗是良好选择。
- 对参考影像上危及器官紧贴靶区的患者,MRgART可能改善靶区剂量覆盖。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: MR-guided adapted radiotherapy (MRgART) using a high field MR-linac has recently become available. We report the estimated delivered fractional dose of the first five prostate cancer patients treated at our centre using MRgART and compare this to C-Arm linac daily Image Guided Radiotherapy (IGRT). METHODS: Patients were treated using adapted treatment plans shaped to their daily anatomy. The treatments were recalculated on an MR image acquired immediately prior to treatment delivery in order to estimate the delivered fractional dose. C-arm linac non-adapted VMAT treatment plans were recalculated on the same MR images to estimate the fractional dose that would have been delivered using conventional radiotherapy techniques using a daily IGRT protocol. RESULTS: 95% and 93% of mandatory target coverage objectives and organ at risk dose constraints were achieved by MRgART and C-arm linac delivered dose estimates, respectively. Both delivery techniques were estimated to have achieved 98% of mandatory Organ At Risk (OAR) dose constraints whereas for the target clinical goals, 86% and 80% were achieved by MRgART and C-arm linac delivered dose estimates. CONCLUSIONS: Prostate MRgART can be delivered using the a high field MR-linac. Radiotherapy performed on a C-arm linac offers a good solution for prostate cancer patients who present with favourable anatomy at the time of reference imaging and demonstrate stable anatomy throughout the course of their treatment. For patients with critical OARs abutting target volumes on their reference image we have demonstrated the potential for a target dose coverage improvement for MRgART compared to C-arm linac treatment.
引用
- Dunlop A, Mitchell A, Tree A, et al. Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: Initial clinical experiences and assessment of delivered doses compared to a C-arm linac. Clin Transl Radiat Oncol. 2020. PMID: 32395640. doi:10.1016/j.ctro.2020.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。